State-by-state friction
Federal legality is not the whole story.
Pharmacies can become more conservative than the federal baseline depending on board scrutiny, sterile compounding posture, and local clinic demand.
West
California
California applies a stricter compounding posture through the Sherman Food, Drug, and Cosmetic Law and aggressive board oversight.
South
Texas
Texas allows compounding activity but state pharmacy scrutiny increases quickly once the FDA flags a peptide for safety or efficacy concerns.
Midwest
Ohio
Ohio has a baseline federal posture but pharmacies report heightened caution around peptides after repeated enforcement attention in regenerative medicine.
South
Florida
Florida remains a major wellness prescribing market, but availability can change quickly when pharmacies tighten risk policies.
Northeast
New York
New York tends to align closely with conservative compliance interpretations for sterile and specialty compounding.
South
Tennessee
Tennessee is active in the wellness and telehealth ecosystem, but access still hinges on what compounding pharmacies are willing to defend.